8-12 November, 2019
ENYO Pharma will attend the AASLD meeting in Boston and announce the presentation of five abstracts (four posters and one oral presentation).
During the conference, ENYO Pharma will also sponsor a Symposium on the 10th of November, to discuss recent advances in the understanding of the replication of Hepatitis B (HBV) and the potential ability of Farnesoid X receptor (FXR) agonists, such as EYP001, to provide a functional cure for HBV. The session “FXR agonist targeting HBV: a new therapeutic class?” will start at 12:30pm on the 10th of November at the Westin Hotel – 10 Huntington Ave Boston. The presentation will be led by the following Key Opinion Leaders (KOLs):
– Prof. Fabien Zoulim (Inserm Lyon): General overview of HBV replication, the role of HBx and cccDNA as targets in the landscape of new HBV treatments
– Prof. Stephan Urban (Heidelberg University): Update on HBV transcription regulation-ready as a target for therapeutic intervention
– Prof. Robert Gish (HepB Foundation): Presentation of the EYP001 FXR agonist phase 1b data as an example of a new therapeutic option in development
The presentations will be followed by an open Q&A session and a lunch (to book a place, you can send an email to firstname.lastname@example.org).”